title: Bone mineral density and associated parameters in pre-pubertal children with asthma treated with long-term fluticasone propionate.
abstract: OBJECTIVE
  The primary aim of the objective of the study was to determine the effects of long-term treatment with the recommended dose of inhaled fluticasone propionate spray usage on bone mineral status in children with asthma.
  
  
  METHODS
  This cross-sectional, case-control study was of 270 pre-pubertal children with asthma, who had used inhaled fluticasone propionate at a mean daily dose of 200 μg (range: 200-350 μg) for at least 5 years. The bone mineral density (BMD) of the lumbar spine was measured by dual-energy X-ray absorptiometry (DEXA). The results were compared to untreated controls (n=200), who were newly diagnosed children with asthma without any corticosteroid treatment.
  
  
  RESULTS
  The 270 study patients (175 males) were aged between 6 and 13 years. The average age (±SEM) was 9.2±0.6 years, and the mean (±SEM) steroid dosage used was 183.3±57.0 μg daily, with 236.5±17.2 g total steroid use during treatment. Between the study and the control groups, no significant difference was observed in BMD (p>0.05).
  
  
  CONCLUSIONS
  The findings suggest that long-term periodical treatment for 5 years with inhaled fluticasone propionate, 100 μg twice daily, in children with asthma revealed no negative effect on bone mineral density by using DEXA.
authors.affiliation: Department of Pediatrics, Division of Pediatric Allergy, Bezmialem Vakif University, Istanbul, Turkey. minozkaya@yahoo.com
authors.forename: E
authors.initials: E
authors.lastname: Ozkaya
authors.forename: E
authors.initials: E
authors.lastname: Çakır
authors.forename: S
authors.initials: S
authors.lastname: Uzuner
authors.forename: U
authors.initials: U
authors.lastname: Erenberk
authors.forename: M R
authors.initials: MR
authors.lastname: Dundaröz
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000730:Androstadienes / Q000008:administration & dosage*; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000175:diagnosis* / Q000188:drug therapy; D015519:Bone Density / Q000187:drug effects*; D002648:Child; D002985:Clinical Protocols; D003430:Cross-Sectional Studies; D000068298:Fluticasone; D006801:Humans; D008161:Lumbosacral Region / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D011379:Prognosis; D011627:Puberty; D011859:Radiography; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey
chemical_list: D000730:Androstadienes; D018926:Anti-Allergic Agents; D000068298:Fluticasone